{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T02:03:06Z","timestamp":1793325786595,"version":"4.5.0"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,20]],"date-time":"2021-10-20T00:00:00Z","timestamp":1634688000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011892","name":"Kaohsiung Chang Gung Memorial Hospital","doi-asserted-by":"publisher","award":["CMRPG8J0061"],"award-info":[{"award-number":["CMRPG8J0061"]}],"id":[{"id":"10.13039\/501100011892","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.biopha.2021.112349","type":"journal-article","created":{"date-parts":[[2021,10,25]],"date-time":"2021-10-25T11:49:01Z","timestamp":1635162541000},"page":"112349","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["Rapamycin attenuates PLA2R activation-mediated podocyte apoptosis via the PI3K\/AKT\/mTOR pathway"],"prefix":"10.1016","volume":"144","author":[{"given":"Terry Ting-Yu","family":"Chiou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"You-Ying","family":"Chau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Bor","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsiang-Hao","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shao-Pei","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Chin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.biopha.2021.112349_bib1","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.kint.2016.09.048","article-title":"Membranous nephropathy: integrating basic science into improved clinical management","volume":"91","author":"Cattran","year":"2017","journal-title":"Kidney Int."},{"issue":"1","key":"10.1016\/j.biopha.2021.112349_bib2","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1053\/j.ajkd.2016.01.030","article-title":"Membranous nephropathy: a journey from bench to bedside","volume":"68","author":"Francis","year":"2016","journal-title":"Am. J. Kidney Dis."},{"issue":"4","key":"10.1016\/j.biopha.2021.112349_bib3","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1681\/ASN.2009121220","article-title":"Antigen identification in membranous nephropathy moves toward targeted monitoring and new therapy","volume":"21","author":"Ronco","year":"2010","journal-title":"J. Am. Soc. Nephrol."},{"issue":"4","key":"10.1016\/j.biopha.2021.112349_bib4","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/S0270-9295(03)00055-X","article-title":"Therapy of membranous nephropathy associated with malignancy and secondary causes","volume":"23","author":"Jefferson","year":"2003","journal-title":"Semin. Nephrol."},{"issue":"4","key":"10.1016\/j.biopha.2021.112349_bib5","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/nrneph.2009.14","article-title":"Membranous nephropathy in systemic lupus erythematosus: a therapeutic enigma","volume":"5","author":"Mok","year":"2009","journal-title":"Nat. Rev. Nephrol."},{"issue":"13","key":"10.1016\/j.biopha.2021.112349_bib6","doi-asserted-by":"crossref","first-page":"22299","DOI":"10.18632\/oncotarget.15397","article-title":"Membranous nephropathy associated with hepatitis C virus infection treated with corticosteroids and Ledipasvir-Sofosbuvir: a case report and review of literature","volume":"8","author":"Weng","year":"2017","journal-title":"Oncotarget"},{"issue":"9","key":"10.1016\/j.biopha.2021.112349_bib7","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0160437","article-title":"A meta-analysis of antiviral therapy for hepatitis B virus-associated membranous nephropathy","volume":"11","author":"Yang","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2021.112349_bib8","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2020.611317","article-title":"Secondary membranous nephropathy. A narrative review","volume":"7","author":"Moroni","year":"2020","journal-title":"Front. Med."},{"issue":"7","key":"10.1016\/j.biopha.2021.112349_bib9","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1093\/ndt\/gfh832","article-title":"Development of glomerulonephritis during anti-TNF-alpha therapy for rheumatoid arthritis","volume":"20","author":"Stokes","year":"2005","journal-title":"Nephrol. Dial. Transpl."},{"issue":"17","key":"10.1016\/j.biopha.2021.112349_bib10","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1001\/jama.1983.03340170069032","article-title":"Membranous glomerulopathy and nephrotic syndrome after captopril therapy","volume":"250","author":"Sturgill","year":"1983","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.biopha.2021.112349_bib11","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa0810457","article-title":"M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy","volume":"361","author":"Beck","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"26","key":"10.1016\/j.biopha.2021.112349_bib12","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1056\/NEJMoa012895","article-title":"Antenatal membranous glomerulonephritis due to anti-neutral endopeptidase antibodies","volume":"346","author":"Debiec","year":"2002","journal-title":"N. Engl. J. Med."},{"issue":"24","key":"10.1016\/j.biopha.2021.112349_bib13","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1056\/NEJMoa1409354","article-title":"Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy","volume":"371","author":"Tomas","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.biopha.2021.112349_bib14","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1172\/JCI85265","article-title":"Autoantibodies against thrombospondin type 1 domain-containing 7A induce membranous nephropathy","volume":"126","author":"Tomas","year":"2016","journal-title":"J. Clin. Investig."},{"issue":"11","key":"10.1016\/j.biopha.2021.112349_bib15","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1681\/ASN.2017010030","article-title":"A heterologous model of thrombospondin type 1 domain-containing 7A-associated membranous nephropathy","volume":"28","author":"Tomas","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"issue":"1","key":"10.1016\/j.biopha.2021.112349_bib16","doi-asserted-by":"crossref","first-page":"6876","DOI":"10.1038\/s41598-017-07028-8","article-title":"PLA2R binds to the annexin A2-S100A10 complex in human podocytes","volume":"7","author":"Fresquet","year":"2017","journal-title":"Sci. Rep."},{"issue":"Suppl","key":"10.1016\/j.biopha.2021.112349_bib17","first-page":"139","article-title":"Kidney disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO clinical practice guideline for glomerulonephritis","volume":"2","year":"2012","journal-title":"Kidney Int."},{"issue":"1","key":"10.1016\/j.biopha.2021.112349_bib18","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1681\/ASN.2013020185","article-title":"Long-term outcomes in idiopathic membranous nephropathy using a restrictive treatment strategy","volume":"25","author":"van den Brand","year":"2014","journal-title":"J. Am. Soc. Nephrol."},{"issue":"2","key":"10.1016\/j.biopha.2021.112349_bib19","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.kint.2018.10.018","article-title":"Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference","volume":"95","author":"Floege","year":"2019","journal-title":"Kidney Int."},{"issue":"4","key":"10.1016\/j.biopha.2021.112349_bib20","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1002\/ijc.21932","article-title":"Curcumin inhibits the mammalian target of rapamycin-mediated signaling pathways in cancer cells","volume":"119","author":"Beevers","year":"2006","journal-title":"Int. J. Cancer"},{"issue":"6","key":"10.1016\/j.biopha.2021.112349_bib21","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.cmet.2016.05.009","article-title":"The mechanistic target of rapamycin: the grand ConducTOR of metabolism and aging","volume":"23","author":"Kennedy","year":"2016","journal-title":"Cell Metab."},{"issue":"3","key":"10.1016\/j.biopha.2021.112349_bib22","doi-asserted-by":"crossref","first-page":"222","DOI":"10.4161\/cbt.2.3.360","article-title":"Rapamycins: mechanism of action and cellular resistance","volume":"2","author":"Huang","year":"2003","journal-title":"Cancer Biol. Ther."},{"issue":"7","key":"10.1016\/j.biopha.2021.112349_bib23","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1681\/ASN.2004030180","article-title":"Rapamycin ameliorates proteinuria-associated tubulointerstitial inflammation and fibrosis in experimental membranous nephropathy","volume":"16","author":"Bonegio","year":"2005","journal-title":"J. Am. Soc. Nephrol."},{"issue":"5","key":"10.1016\/j.biopha.2021.112349_bib24","doi-asserted-by":"crossref","first-page":"5793","DOI":"10.3892\/mmr.2017.7367","article-title":"Association of BAFF with PI3K\/Akt\/mTOR signaling in lupus nephritis","volume":"16","author":"Ge","year":"2017","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.biopha.2021.112349_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2019.109468","article-title":"The PI3K\/Akt\/mTOR pathway in polycystic kidney disease: a complex interaction with polycystins and primary cilium","volume":"66","author":"Margaria","year":"2020","journal-title":"Cell Signal."},{"issue":"1","key":"10.1016\/j.biopha.2021.112349_bib26","first-page":"835","article-title":"ROS induces epithelial-mesenchymal transition via the TGF-beta1\/PI3K\/Akt\/mTOR pathway in diabetic nephropathy","volume":"17","author":"Lu","year":"2019","journal-title":"Exp. Ther. Med."},{"issue":"6","key":"10.1016\/j.biopha.2021.112349_bib27","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1681\/ASN.2017010027","article-title":"New insights into podocyte biology in glomerular health and disease","volume":"28","author":"Assady","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.biopha.2021.112349_bib28","doi-asserted-by":"crossref","first-page":"6660","DOI":"10.1038\/srep06660","article-title":"sPLA2 IB induces human podocyte apoptosis via the M-type phospholipase A2 receptor","volume":"4","author":"Pan","year":"2014","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2021.112349_bib29","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/5286972","article-title":"The roles of PI3K\/AKT\/mTOR and MAPK\/ERK signaling pathways in human pheochromocytomas","volume":"2016","author":"Du","year":"2016","journal-title":"Int. J. Endocrinol."},{"issue":"12","key":"10.1016\/j.biopha.2021.112349_bib30","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1007\/s00109-008-0399-y","article-title":"Mechanisms of angiotensin II signaling on cytoskeleton of podocytes","volume":"86","author":"Hsu","year":"2008","journal-title":"J. Mol. Med."},{"issue":"1","key":"10.1016\/j.biopha.2021.112349_bib31","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1523-1755.2004.00711.x","article-title":"Stable expression of nephrin and localization to cell-cell contacts in novel murine podocyte cell lines","volume":"66","author":"Schiwek","year":"2004","journal-title":"Kidney Int."},{"issue":"9","key":"10.1016\/j.biopha.2021.112349_bib32","doi-asserted-by":"crossref","DOI":"10.3390\/cells8091085","article-title":"Empagliflozin protects HK-2 cells from high glucose-mediated injuries via a mitochondrial mechanism","volume":"8","author":"Lee","year":"2019","journal-title":"Cells"},{"issue":"3","key":"10.1016\/j.biopha.2021.112349_bib33","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/s41418-017-0012-4","article-title":"Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018","volume":"25","author":"Galluzzi","year":"2018","journal-title":"Cell Death Differ."},{"issue":"17","key":"10.1016\/j.biopha.2021.112349_bib34","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20174133","article-title":"A cell\u2019s fate: an overview of the molecular biology and genetics of apoptosis","volume":"20","author":"Cavalcante","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.biopha.2021.112349_bib35","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1681\/ASN.2005010028","article-title":"Management of membranous nephropathy: when and what for treatment","volume":"16","author":"Cattran","year":"2005","journal-title":"J. Am. Soc. Nephrol."},{"issue":"5","key":"10.1016\/j.biopha.2021.112349_bib36","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1046\/j.1523-1755.2001.0590051983.x","article-title":"Idiopathic membranous glomerulonephritis","volume":"59","author":"Cattran","year":"2001","journal-title":"Kidney Int."},{"issue":"3","key":"10.1016\/j.biopha.2021.112349_bib37","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s10157-020-01854-3","article-title":"New insight into podocyte slit diaphragm, a therapeutic target of proteinuria","volume":"24","author":"Kawachi","year":"2020","journal-title":"Clin. Exp. Nephrol."},{"issue":"5","key":"10.1016\/j.biopha.2021.112349_bib38","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1080\/15548627.2019.1580512","article-title":"Podocytes and autophagy: a potential therapeutic target in lupus nephritis","volume":"15","author":"Zhou","year":"2019","journal-title":"Autophagy"},{"key":"10.1016\/j.biopha.2021.112349_bib39","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/3560238","article-title":"Podocyte autophagy: a potential therapeutic target to prevent the progression of diabetic nephropathy","volume":"2017","author":"Liu","year":"2017","journal-title":"J. Diabetes Res."},{"key":"10.1016\/j.biopha.2021.112349_bib40","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.20105.1","article-title":"Podocyte RhoGTPases: new therapeutic targets for nephrotic syndrome?","volume":"8","author":"Saleem","year":"2019","journal-title":"F1000Res"},{"issue":"6","key":"10.1016\/j.biopha.2021.112349_bib41","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1053\/j.ajkd.2019.05.021","article-title":"Treatment of membranous nephropathy in patients with THSD7A antibodies using immunoadsorption","volume":"74","author":"Weinmann-Menke","year":"2019","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.biopha.2021.112349_bib42","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.atherosclerosissup.2019.08.027","article-title":"Immunoadsorption in nephrotic syndrome: where are we now and where are we going from here?","volume":"Suppl 40","author":"Kronbichler","year":"2019","journal-title":"Atheroscler"},{"issue":"8","key":"10.1016\/j.biopha.2021.112349_bib43","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1681\/ASN.2017121338","article-title":"The human FSGS-causing ANLN R431C mutation induces dysregulated PI3K\/AKT\/mTOR\/Rac1 signaling in podocytes","volume":"29","author":"Hall","year":"2018","journal-title":"J. Am. Soc. Nephrol."},{"issue":"4","key":"10.1016\/j.biopha.2021.112349_bib44","first-page":"405","article-title":"p66Shc regulates podocyte autophagy in high glucose environment through the Notch-PTEN-PI3K\/Akt\/mTOR pathway","volume":"35","author":"Zheng","year":"2020","journal-title":"Histol. Histopathol."},{"key":"10.1016\/j.biopha.2021.112349_bib45","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/7069052","article-title":"Curcumin improves the renal autophagy in rat experimental membranous nephropathy via regulating the PI3K\/AKT\/mTOR and Nrf2\/HO-1 signaling pathways","volume":"2020","author":"Di Tu","year":"2020","journal-title":"Biomed Res. Int."},{"issue":"7","key":"10.1016\/j.biopha.2021.112349_bib46","doi-asserted-by":"crossref","first-page":"5241","DOI":"10.1016\/S0021-9258(17)37680-9","article-title":"A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002)","volume":"269","author":"Vlahos","year":"1994","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.biopha.2021.112349_bib47","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12943-019-0954-x","article-title":"Targeting PI3K in cancer: mechanisms and advances in clinical trials","volume":"18","author":"Yang","year":"2019","journal-title":"Mol. Cancer"},{"issue":"2","key":"10.1016\/j.biopha.2021.112349_bib48","doi-asserted-by":"crossref","first-page":"F205","DOI":"10.1152\/ajprenal.90005.2013","article-title":"Interplay between the Notch and PI3K\/Akt pathways in high glucose-induced podocyte apoptosis","volume":"306","author":"Wang","year":"2014","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"10.1016\/j.biopha.2021.112349_bib49","article-title":"Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients","volume":"12","author":"Hahn","year":"2019","journal-title":"Cochrane Database Syst. Rev."},{"issue":"1","key":"10.1016\/j.biopha.2021.112349_bib50","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1046\/j.1523-1755.2001.00460.x","article-title":"Rapamycin in transplantation: a review of the evidence","volume":"59","author":"Saunders","year":"2001","journal-title":"Kidney Int."},{"issue":"2S Suppl 1","key":"10.1016\/j.biopha.2021.112349_bib51","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1097\/TP.0000000000001690","article-title":"mTOR inhibition and clinical transplantation: liver","volume":"102","author":"Nashan","year":"2018","journal-title":"Transplantation"},{"issue":"3","key":"10.1016\/j.biopha.2021.112349_bib52","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1517\/14740338.2016.1132698","article-title":"Safety of mTOR inhibitors in adult solid organ transplantation","volume":"15","author":"Ventura-Aguiar","year":"2016","journal-title":"Expert Opin. Drug Saf."},{"issue":"34","key":"10.1016\/j.biopha.2021.112349_bib53","doi-asserted-by":"crossref","first-page":"4798","DOI":"10.1038\/sj.onc.1209608","article-title":"Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy","volume":"25","author":"Fulda","year":"2006","journal-title":"Oncogene"},{"issue":"6805","key":"10.1016\/j.biopha.2021.112349_bib54","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/35037710","article-title":"The biochemistry of apoptosis","volume":"407","author":"Hengartner","year":"2000","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.biopha.2021.112349_bib55","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.bbamcr.2011.01.026","article-title":"Caspase-8 and bid: caught in the act between death receptors and mitochondria","volume":"1813","author":"Kantari","year":"2011","journal-title":"Biochim. Biophys. Acta"},{"issue":"4","key":"10.1016\/j.biopha.2021.112349_bib56","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1083\/jcb.200803129","article-title":"Cardiolipin provides an essential activating platform for caspase-8 on mitochondria","volume":"183","author":"Gonzalvez","year":"2008","journal-title":"J. Cell Biol."},{"issue":"6","key":"10.1016\/j.biopha.2021.112349_bib57","doi-asserted-by":"crossref","first-page":"4351","DOI":"10.1074\/jbc.M108947200","article-title":"Inactivation of caspase-8 on mitochondria of Bcl-xL-expressing MCF7-Fas cells: role for the bifunctional apoptosis regulator protein","volume":"277","author":"Stegh","year":"2002","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.biopha.2021.112349_bib58","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/sj.emboj.7601504","article-title":"FLASH links the CD95 signaling pathway to the cell nucleus and nuclear bodies","volume":"26","author":"Milovic-Holm","year":"2007","journal-title":"EMBO J."},{"issue":"2","key":"10.1016\/j.biopha.2021.112349_bib59","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.molmed.2005.12.003","article-title":"MasterCARD: a priceless link to innate immunity","volume":"12","author":"Hiscott","year":"2006","journal-title":"Trends Mol. Med."},{"issue":"11","key":"10.1016\/j.biopha.2021.112349_bib60","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1038\/sj.cdd.4400739","article-title":"BID-dependent and BID-independent pathways for BAX insertion into mitochondria","volume":"7","author":"Ruffolo","year":"2000","journal-title":"Cell Death Differ."},{"issue":"6","key":"10.1016\/j.biopha.2021.112349_bib61","doi-asserted-by":"crossref","first-page":"983","DOI":"10.2215\/CJN.11761116","article-title":"Primary membranous nephropathy","volume":"12","author":"Couser","year":"2017","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"3","key":"10.1016\/j.biopha.2021.112349_bib62","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1681\/ASN.V93444","article-title":"A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy","volume":"9","author":"Ponticelli","year":"1998","journal-title":"J. Am. Soc. Nephrol."},{"issue":"11","key":"10.1016\/j.biopha.2021.112349_bib63","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1080\/17512433.2016.1225497","article-title":"Pharmacological treatment of primary membranous nephropathy in 2016","volume":"9","author":"van de Logt","year":"2016","journal-title":"Expert Rev. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.biopha.2021.112349_bib64","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa1814427","article-title":"Rituximab or cyclosporine in the treatment of membranous nephropathy","volume":"381","author":"Fervenza","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.biopha.2021.112349_bib65","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.ekir.2020.12.035","article-title":"Rituximab in membranous nephropathy","volume":"6","author":"Gauckler","year":"2021","journal-title":"Kidney Int. Rep."},{"issue":"4","key":"10.1016\/j.biopha.2021.112349_bib66","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.kint.2020.10.014","article-title":"The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy","volume":"99","author":"Fernandez-Juarez","year":"2021","journal-title":"Kidney Int."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332221011331?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332221011331?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T12:45:58Z","timestamp":1760100358000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332221011331"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":66,"alternative-id":["S0753332221011331"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2021.112349","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rapamycin attenuates PLA2R activation-mediated podocyte apoptosis via the PI3K\/AKT\/mTOR pathway","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2021.112349","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"112349"}}